Menu

Biotech

HomeAll PostsBiotech

Renegade.bio and Metabolomic Diagnostics Partner to Develop a Novel Preeclampsia Risk Screening Test

Biotech, News, Pregnancy February 21, 2022
Share

Biotech firm Renegade.bio and Metabolomic Diagnostics are teaming up to develop a novel pre-eclampsia risk screening test, with plans to launch in the U.S. in late 2022. The test will be jointly developed specifically for the U.S. population, improving upon available assessments by creating a personalized risk profile for individuals. It measures a panel of biomarkers in blood that serves as early…

Biotech Company Amyris Gets Serious about the Menopause Market with the Acquisition of Menolabs

Biotech, Menopause, News January 24, 2022
Share

Amyris, a synthetic biotech company breaking into Clean Health & Beauty, is getting serious about the menopause market with the acquisition on Menolabs, who have developed line of all natural, proprietary supplements focused on treating perimenopause and menopause symptoms as well as a menopause health tracking app, and a community forum. Amyris previously shared its intention of launching a new consumer brand…

Biotech: All Eyes on Ovarian Health and Biology

Biotech, News, Women's Health January 23, 2022
Share

Ovarian biology is getting quite a bit of attention lately. And rightfully so given the large potential impact innovation in this space can have on the lives of literally every single woman on this planet. So it truly is about time we spend some time on ovarian health here on this blog, share an overview and some insights into the space with…

Celmatix, Evotec & Bayer Just Hit Another Milestone in Their Quest to Develop a First-in-Class Drug for PCOS

Biotech, Chronic Conditions, News, Partnership January 18, 2022
Share

Celmatix, a New York-based pre-clinical stage biotech company focused on ovarian biology, has announced today that a novel PCOS target identified as part of its five-year, multi-target alliance with Evotec, has progressed into hit-identification. It may still be early in the process, but what this milestone essentially means is that Celmatix, Evotec and pharma leader Bayer, who formed a “PCOS alliance” around…

BioInnovation Institute Receives a Grant from the Gates Foundation to Launch a New Initiative Focused on Women’s Health

Biotech, Ecosystem, News January 13, 2022
Share

BioInnovation Institute (BII), a non-for profit Foundation known for incubating and advancing world-class life science research, has received a grant from the Bill & Melinda Gates Foundation to accelerate efforts to discover translational world-class research to identify new technologies and solutions that can improve the health of women and girls across the world, including low-income countries.  The grant supports BII’s vision to strengthen the…

Gameto Raises $23M to Redefine Reproductive Longevity with Reprogrammed Ovarian Cells

Biotech, Hormonal Health, Investment, Menopause, News, Women's Health January 10, 2022
Share

Gameto, a biotechnology startup solving the problem of accelerated ovarian aging to change the trajectory of women’s health and equality, today announced that it has raised a $20M in Series A funding led by Future Ventures, with participation from Bold Capital Partners, Lux Capital, Plum Alley, TA Ventures, Overwater Ventures, Robert Nelsen and Anne Wojcicki. Gameto also raised $3M in Seed funding in March 2020 from a range of notable investors…

New Study: Mirvie Can Predict Pregnancy Complications Months Before They Happen

Biotech, News, Pregnancy, Research January 10, 2022
Share

Mirvie, a pioneer in predicting unexpected pregnancy complications, has announced the publication of a study in Nature proving the proprietary Mirvie RNA platform is first to predict unexpected complications by revealing the underlying biology of each pregnancy. The research analyzed the largest and most diverse dataset of maternal transcriptomes to date. The platform opens a new window into pregnancy health for women to act…

Women’s Health Biotech Company ObsEva Is Added to the NASDAQ Biotechnology Index

Biotech, Gynecological Health, News, Women's Health December 27, 2021
Share

ObsEva has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. The biotech company develops and commercializes novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment…